1)Hato T, et al:Risk factors for skin, mucosal, and organ bleeding in adults with primary ITP;A nationwide study in Japan. Blood Adv 4:1648-1655, 2020
2)山崎宏人:再生不良性貧血の治療.日内会誌108:1205-1211, 2019
3)Rodeghiero F, et al:Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children;Report from an international working group. Blood 113:2386-2393, 2009
4)Kashiwagi H, Tomiyama Y:Pathophysiology and management of primary immune thrombocytopenia. Int J Hematol 98:24-33, 2013
5)柏木浩和:特発性血小板減少性紫斑病(ITP)の病態と治療.日内会誌109:1347-1354, 2020
6)Kuwana M, et al:Preliminary laboratory based diagnostic criteria for immune thrombocytopenic purpura;Evaluation by multi-center prospective study. J Thromb Haemost 4:1936-1943, 2006
7)Sakuragi M, et al:Clinical significance of IPF% or RP% measurement in distinguishing primary immune thrombocytopenia from aplastic thrombocytopenic disorders. Int J Hematol 101:369-375, 2015
8)Kurata Y, et al:Diagnostic value of tests for reticulated platelets, plasma glycocalicin, and thrombopoietin levels for discriminating between hyperdestructive and hypoplastic thrombocytopenia. Am J Clin Pathol 115:656-664, 2001
9)柏木浩和,他:成人特発性血小板減少性紫斑病治療の参照ガイド2019改訂版.臨床血液60:877-896, 2019
10)Neunert C, et al: American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3:3829-3866, 2019
11)Provan D, et al:Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 3:3780-3817, 2019
12)Kuter DJ:Exacerbation of immune thrombocytopenia following COVID-19 vaccination. Br J Haematol. 2021. Online ahead of print.